A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above
Greece, Spain, France, Germany, Italy, Hungary, Denmark, Sweden
Condition studied
Recurrence of Clostridioides difficile Infection
Investigational medicinal product(s)
Placebo for AZD5148AZD5148
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
First occurrence of recurrence of C. difficile infection
Endpoint detail
Sustained clinical cure (ie, achievement of initial clinical cure + no recurrent C. difficile infection)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.